<code id='D0839BB213'></code><style id='D0839BB213'></style>
    • <acronym id='D0839BB213'></acronym>
      <center id='D0839BB213'><center id='D0839BB213'><tfoot id='D0839BB213'></tfoot></center><abbr id='D0839BB213'><dir id='D0839BB213'><tfoot id='D0839BB213'></tfoot><noframes id='D0839BB213'>

    • <optgroup id='D0839BB213'><strike id='D0839BB213'><sup id='D0839BB213'></sup></strike><code id='D0839BB213'></code></optgroup>
        1. <b id='D0839BB213'><label id='D0839BB213'><select id='D0839BB213'><dt id='D0839BB213'><span id='D0839BB213'></span></dt></select></label></b><u id='D0839BB213'></u>
          <i id='D0839BB213'><strike id='D0839BB213'><tt id='D0839BB213'><pre id='D0839BB213'></pre></tt></strike></i>

          Home / entertainment / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:15872

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In